NHS rolls out ‘COVID-friendly’ cancer treatments
NHS chief executive, Sir Simon Stevens has announced the roll-out [...]
Survivorship and immune checkpoint inhibitors
In a study reported in the August issue of the [...]
The impact of COVID-19 pandemic on treatment for metastatic kidney cancer
A recent online survey involving 41 kidney cancer experts worldwide [...]
Funding approved for avelumab in combination with axitinib for untreated advanced kidney cancer
KCSN are formal consultants to NICE and part of the [...]
Combination of potential biomarkers may help predict response to immunotherapy in kidney cancer
Currently, it is difficult for clinicians to decide which patients [...]
Long term follow-up of immune-related adverse events in cancer survivors
In this study carried out at a single hospital 217 [...]
COVID-19 testing needed for kidney cancer patients
This article from Oncology Nursing News reports the results of [...]
Inflammatory biomarkers for non-metastatic kidney cancer
This study looked at inflammatory biomarkers in the blood for [...]
Comparison of first-line immunotherapy combinations for metastatic kidney cancer
This meta-analysis of first-line immunotherapy trials was published in the [...]
Atexolizumab plus bevacizumab for sarcomatoid kidney cancer
A study published in European Urology in July looks at [...]
